中华普通外科杂志
中華普通外科雜誌
중화보통외과잡지
CHINESE JOURNAL OF GENERAL SURGERY
2009年
6期
484-488
,共5页
陆宁%韩文兰%陈彩萍%邬万新%温晓伟%张燕萍%唐正英%袁琳娜%喻其霞%郭文利
陸寧%韓文蘭%陳綵萍%鄔萬新%溫曉偉%張燕萍%唐正英%袁琳娜%喻其霞%郭文利
륙저%한문란%진채평%오만신%온효위%장연평%당정영%원림나%유기하%곽문리
乳腺肿瘤%受体,雌激素%受体,孕激素%基因,erbB-2
乳腺腫瘤%受體,雌激素%受體,孕激素%基因,erbB-2
유선종류%수체,자격소%수체,잉격소%기인,erbB-2
Breast neoplasms%Receptors,estrogen%Receptor,progestogen%Genes,erbB-2
目的 评价雌、孕激素受体和Her-2表达均阴性乳腺癌(triple-negative breast cancer,TNBC)的临床病理特征及其对预后的影响.方法 500例乳腺癌采用免疫组化筛选TNBC,观察TNBC的临床病理特征,并对其中243例乳腺癌进行临床随访. 结果 500例乳腺癌中TNBC占17.6%(88/500).组织学类型主要为浸润性导管癌(NOS)、化生性癌和髓样癌.组织分级Ⅲ级占72.7%(64/88),高于激素受体阳性组和Her-2高表达组(P=0.000).TNBC中CK5/6阳性率30.7%(27/88),EGFR阳性率34.1%(30/88).TNBC中ERCC1和KIT阳性率分别为28.4%(25/88)和34.1%(30/88),均分别高于激素受体阳性组和Her-2高表达组(P=0.032和P=0.026).TNBC 3年累积生存率为71.5%,低于激素受体阳性组(P=0.021),与Her-2高表达组差异无统计学意义(P=0.474). 结论 TNBC是一类具有高侵袭性病理特征和预后不良的乳腺癌;部分病例表达EGFR和ERCC1.
目的 評價雌、孕激素受體和Her-2錶達均陰性乳腺癌(triple-negative breast cancer,TNBC)的臨床病理特徵及其對預後的影響.方法 500例乳腺癌採用免疫組化篩選TNBC,觀察TNBC的臨床病理特徵,併對其中243例乳腺癌進行臨床隨訪. 結果 500例乳腺癌中TNBC佔17.6%(88/500).組織學類型主要為浸潤性導管癌(NOS)、化生性癌和髓樣癌.組織分級Ⅲ級佔72.7%(64/88),高于激素受體暘性組和Her-2高錶達組(P=0.000).TNBC中CK5/6暘性率30.7%(27/88),EGFR暘性率34.1%(30/88).TNBC中ERCC1和KIT暘性率分彆為28.4%(25/88)和34.1%(30/88),均分彆高于激素受體暘性組和Her-2高錶達組(P=0.032和P=0.026).TNBC 3年纍積生存率為71.5%,低于激素受體暘性組(P=0.021),與Her-2高錶達組差異無統計學意義(P=0.474). 結論 TNBC是一類具有高侵襲性病理特徵和預後不良的乳腺癌;部分病例錶達EGFR和ERCC1.
목적 평개자、잉격소수체화Her-2표체균음성유선암(triple-negative breast cancer,TNBC)적림상병리특정급기대예후적영향.방법 500례유선암채용면역조화사선TNBC,관찰TNBC적림상병리특정,병대기중243례유선암진행림상수방. 결과 500례유선암중TNBC점17.6%(88/500).조직학류형주요위침윤성도관암(NOS)、화생성암화수양암.조직분급Ⅲ급점72.7%(64/88),고우격소수체양성조화Her-2고표체조(P=0.000).TNBC중CK5/6양성솔30.7%(27/88),EGFR양성솔34.1%(30/88).TNBC중ERCC1화KIT양성솔분별위28.4%(25/88)화34.1%(30/88),균분별고우격소수체양성조화Her-2고표체조(P=0.032화P=0.026).TNBC 3년루적생존솔위71.5%,저우격소수체양성조(P=0.021),여Her-2고표체조차이무통계학의의(P=0.474). 결론 TNBC시일류구유고침습성병리특정화예후불량적유선암;부분병례표체EGFR화ERCC1.
Objective To study the clinicopathologic characteristics of triple-negative breast cancer (TNBC) and its value in the prediction of prognosis. Method In this study,500 cases of female breast cancers were examined immunohistochcmically for the TNBC. The clinicopathologic characteristics of the 243 TNBC cases were inspected. Results TNBC accounted for 17.6% (88/500) of the 500 breast cancers. The histological types of the TNBC included mainly infihrative ductal carcinoma, metaplastic carcinoma and medullar carcinoma. Among those, histological grade Ⅲ accounted for 72.7% (64/88) of all the TNBC and was more common than that in hormone receptor positive breast cancers (HR+ group ) and Her-2 overexpression breast cancers (Her-2 group)(P=0.000). The positive rates of CK5/6 and EGFR in the TNBC were 30.7% (27/88) and 34.1% (30/88), respectively. The positive rates of ERCC1 and KIT in the TNBC were 28.4% (25/88) and 34.1% (30/88), respectively, Both of which were higher than those in the HR + group and Her-2 group, respectively (P=0.032 and P=0.026). 3-year survival rate of the TNBC was 71.5% and it was lower than that of HR group (P=0.021) and not significantly different from that of Her-2 group (P=0.474). Conclusions TNBC is the breast cancer with high aggressive pathologic futures and poor prognosis. EGFR and ERCC1 expression were positive in a portion of TNBC cases.
